Cargando…
IgG Fusion Proteins for Brain Delivery of Biologics via Blood–Brain Barrier Receptor-Mediated Transport
The treatment of neurological disorders with large-molecule biotherapeutics requires that the therapeutic drug be transported across the blood–brain barrier (BBB). However, recombinant biotherapeutics, such as neurotrophins, enzymes, decoy receptors, and monoclonal antibodies (MAb), do not cross the...
Autor principal: | Boado, Ruben J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322584/ https://www.ncbi.nlm.nih.gov/pubmed/35890374 http://dx.doi.org/10.3390/pharmaceutics14071476 |
Ejemplares similares
-
Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery
por: Boado, Ruben J., et al.
Publicado: (2019) -
Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery
por: Pardridge, William M., et al.
Publicado: (2009) -
Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro
por: Takeshita, Yukio, et al.
Publicado: (2016) -
Receptor-mediated transport of IgG
por: Rodewald, R., et al.
Publicado: (1984) -
Insulin Receptor Antibody–Sulfamidase Fusion
Protein Penetrates the Primate Blood–Brain Barrier and Reduces
Glycosoaminoglycans in Sanfilippo Type A Cells
por: Boado, Ruben J., et al.
Publicado: (2014)